CO2019011271A2 - Análogos de deutetrabenazina, su preparación y uso - Google Patents
Análogos de deutetrabenazina, su preparación y usoInfo
- Publication number
- CO2019011271A2 CO2019011271A2 CONC2019/0011271A CO2019011271A CO2019011271A2 CO 2019011271 A2 CO2019011271 A2 CO 2019011271A2 CO 2019011271 A CO2019011271 A CO 2019011271A CO 2019011271 A2 CO2019011271 A2 CO 2019011271A2
- Authority
- CO
- Colombia
- Prior art keywords
- deutetrabenazine
- analogs
- preparation
- compositions
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Pens And Brushes (AREA)
- Machine Translation (AREA)
Abstract
La divulgación se dirige a análogos de deutetrabenazina, composiciones que comprenden los mismos y métodos para detectar los mismos en composiciones que comprenden deutetrabenazina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762471484P | 2017-03-15 | 2017-03-15 | |
PCT/US2018/022562 WO2018170214A1 (en) | 2017-03-15 | 2018-03-15 | Analogs of deutetrabenazine, their preparation and use |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019011271A2 true CO2019011271A2 (es) | 2020-02-28 |
Family
ID=61873991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0011271A CO2019011271A2 (es) | 2017-03-15 | 2019-10-10 | Análogos de deutetrabenazina, su preparación y uso |
Country Status (20)
Country | Link |
---|---|
US (4) | US11813232B2 (es) |
EP (1) | EP3596077A1 (es) |
JP (3) | JP7608050B2 (es) |
KR (2) | KR20230003308A (es) |
CN (1) | CN110709398A (es) |
AR (1) | AR111182A1 (es) |
AU (2) | AU2018236336B2 (es) |
BR (1) | BR112019018966A2 (es) |
CA (1) | CA3056612A1 (es) |
CL (1) | CL2019002629A1 (es) |
CO (1) | CO2019011271A2 (es) |
EA (1) | EA201992168A1 (es) |
IL (1) | IL269132A (es) |
MX (1) | MX2019010913A (es) |
PE (1) | PE20191819A1 (es) |
SG (1) | SG11201908477QA (es) |
TW (1) | TWI772382B (es) |
UA (1) | UA127052C2 (es) |
WO (1) | WO2018170214A1 (es) |
ZA (1) | ZA201906326B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021007063A (es) * | 2018-12-13 | 2021-12-10 | Auspex Pharmaceuticals Inc | Deutetrabenazina para el tratamiento de la discinesia en la paralisis cerebral. |
WO2020165807A1 (en) * | 2019-02-14 | 2020-08-20 | Dr. Reddy's Laboratories Limited | Solid forms of deutetrabenazine and process for the preparation thereof |
WO2021252741A1 (en) * | 2020-06-10 | 2021-12-16 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2081929T3 (pl) | 2006-11-08 | 2013-06-28 | Neurocrine Biosciences Inc | Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania |
ES2652289T3 (es) * | 2008-09-18 | 2018-02-01 | Auspex Pharmaceuticals, Inc. | Derivados deuterados de benzoquinolina como inhibidores del transportador de monoamina vesicular 2 |
US20120003330A1 (en) * | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
WO2012081031A1 (en) * | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
CN104684555A (zh) * | 2012-09-18 | 2015-06-03 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学 |
US9550780B2 (en) * | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
JP6542222B2 (ja) * | 2013-12-03 | 2019-07-10 | オースペックス ファーマシューティカルズ インコーポレイテッド | ベンゾキノリン化合物の製造方法 |
IL305352A (en) | 2015-03-06 | 2023-10-01 | Auspex Pharmaceuticals Inc | Methods for the treatment of abnormal involuntary movement disorders |
-
2018
- 2018-03-15 AR ARP180100611A patent/AR111182A1/es unknown
- 2018-03-15 CN CN201880018609.8A patent/CN110709398A/zh active Pending
- 2018-03-15 US US15/922,329 patent/US11813232B2/en active Active
- 2018-03-15 KR KR1020227043234A patent/KR20230003308A/ko not_active Ceased
- 2018-03-15 TW TW107108832A patent/TWI772382B/zh active
- 2018-03-15 PE PE2019001871A patent/PE20191819A1/es unknown
- 2018-03-15 EP EP18715393.7A patent/EP3596077A1/en active Pending
- 2018-03-15 SG SG11201908477Q patent/SG11201908477QA/en unknown
- 2018-03-15 WO PCT/US2018/022562 patent/WO2018170214A1/en active Application Filing
- 2018-03-15 BR BR112019018966A patent/BR112019018966A2/pt active Search and Examination
- 2018-03-15 UA UAA201910309A patent/UA127052C2/uk unknown
- 2018-03-15 EA EA201992168A patent/EA201992168A1/ru unknown
- 2018-03-15 MX MX2019010913A patent/MX2019010913A/es unknown
- 2018-03-15 JP JP2019550774A patent/JP7608050B2/ja active Active
- 2018-03-15 KR KR1020197030354A patent/KR20200003791A/ko not_active Ceased
- 2018-03-15 AU AU2018236336A patent/AU2018236336B2/en active Active
- 2018-03-15 CA CA3056612A patent/CA3056612A1/en active Pending
-
2019
- 2019-09-04 IL IL26913219A patent/IL269132A/en unknown
- 2019-09-13 CL CL2019002629A patent/CL2019002629A1/es unknown
- 2019-09-25 US US16/582,362 patent/US11179386B2/en active Active
- 2019-09-25 ZA ZA2019/06326A patent/ZA201906326B/en unknown
- 2019-10-10 CO CONC2019/0011271A patent/CO2019011271A2/es unknown
-
2021
- 2021-10-21 US US17/507,037 patent/US20220040170A1/en active Pending
- 2021-11-30 US US17/537,663 patent/US20220088006A1/en not_active Abandoned
-
2022
- 2022-05-18 AU AU2022203369A patent/AU2022203369B2/en active Active
- 2022-11-04 JP JP2022177578A patent/JP2023010754A/ja active Pending
-
2024
- 2024-01-30 JP JP2024011974A patent/JP7631572B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023001910A1 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
CO2018006051A2 (es) | Compuestos inhibidores de la quinasa de unión a tank | |
CL2017003356A1 (es) | Moduladores cot y métodos de uso de los mismos | |
DOP2017000298A (es) | Reguladores de nrf2 | |
CR20160419A (es) | Nuevos compuestos biciclicos | |
CO2019012957A2 (es) | Inhibidores de quinasa y usos de los mismos | |
CR20150436A (es) | Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo | |
NI201400125A (es) | Antagonistas de st2l y métodos de uso | |
DOP2015000219A (es) | Compuestos de heteroarilo y sus usos | |
MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
UY34669A (es) | COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO. | |
UY37410A (es) | Antagonistas de trpv4 | |
CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
CR20170076A (es) | Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
UY38031A (es) | Hidroxiisoxazolinas y derivados de estos | |
DOP2017000073A (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
UY37015A (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
ECSP18074962A (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
CO2019011271A2 (es) | Análogos de deutetrabenazina, su preparación y uso | |
MX2017000862A (es) | Formulacion de factor viii. | |
MX2016003215A (es) | Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion. | |
UY34761A (es) | Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos. | |
AR108616A1 (es) | Formulación combinada de tres compuestos antivirales | |
CO2017002963A2 (es) | Espiro-tiazolonas |